NeuPath Health Valuation

Q: What is the Fair Price of NPTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

NPTH (CA$0.2) is trading below our estimate of [[fair value]] (CA$0.58)

Is NPTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NPTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NPTH (CA$0.2) is trading below our estimate of fair value (CA$0.58)

Significantly Below Fair Value: NPTH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NPTH?

Key metric: As NPTH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NPTH. This is calculated by dividing NPTH's market cap by their current revenue.
What is NPTH's PS Ratio?
PS Ratio	0.2x
Sales	CA$70.73m
Market Cap	CA$11.28m

NPTH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	9.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does NPTH's PS Ratio compare to its peers?

The above table shows the PS ratio for NPTH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.5x
NLH Nova Leap Health	0.6x	n/a	CA$23.3m
PHA Premier Health of America	0.05x	2.1%	CA$7.2m
JUMP Leveljump Healthcare	0.3x	n/a	CA$4.8m
ARC ARCpoint	1.1x	n/a	CA$10.0m
NPTH NeuPath Health	0.2x	n/a	CA$11.3m

Price-To-Sales vs Peers: NPTH is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does NPTH's PS Ratio compare vs other companies in the CA Healthcare Industry?

9 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	1.1x	9.5%
NPTH NeuPath Health	0.2x	n/a	US$7.92m
DOC CloudMD Software & Services	0.1x	n/a	US$7.82m
PHA Premier Health of America	0.05x	2.1%	US$5.07m

9 Companies		Estimated Growth	Market Cap
Industry Avg.	1.1x	57.2%
NPTH NeuPath Health	0.2x	n/a	US$7.92m

No more companies

Price-To-Sales vs Industry: NPTH is good value based on its Price-To-Sales Ratio (0.2x) compared to the North American Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is NPTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NPTH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NPTH's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.